CTOs on the Move

Taro Pharmaceuticals (HQ)

www.tarousa.com

 
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tarousa.com
  • 3 Skyline Dr Ste 120
    Hawthorne, NY USA 10532
  • Phone: 914.345.9001

Executives

Name Title Contact Details

Similar Companies

Quantum Immunologics

Quantum Immunologics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neponset Controls Inc

Neponset Controls Inc is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated Viral Protection

World-Leading Biodefense Indoor Air Protection System™ Scientifically proven to destroy COVID-19 (99.999%) and Anthrax spores (99.98%) instantaneously in a single pass. Learn More Scientifically proven to Kill Sars-CoV-2, the virus that causes COVID-19...

OnSite Waste Technologies

Save time, money and resources with the smarter, simpler, and safer way to handle regulated medical waste

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.